Hiroshi Mabuchi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hiroshi Mabuchi has a total of 168 co-authors. Here are the top co-authors by number of shared publications:
Junji Koizumi
General Medicine, Graduate School of Medical Science, Kanazawa University, Japan
10 shared publications- Akihiro Inazu
Department of Clinical Laboratory Science, Graduate School of Medical Science, Kanazawa University
7 shared publications Tadayoshi Takegoshi
6 shared publicationsAtsushi Nohara
Department of Lipidology, Graduate School of Medical Science, Kanazawa University, Kanazawa 920-8640, Japan
5 shared publicationsHidekazu Ino
5 shared publicationsMasa-Aki Kawashiri
Division of Cardiovascular Medicine, Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan
5 shared publications
Latest Publications
- 1 October 2017
- Published by Elsevier in Atherosclerosis
- Vol. 265, 225-230
Impact of evolocumab treatment on low-density lipoprotein cholesterol levels in heterozygous familial hypercholesterolemic patients withdrawing from regular apheresis
- 1 October 2017
- Published by Elsevier in Atherosclerosis
- Vol. 265, 225-230
Impact of evolocumab treatment on low-density lipoprotein cholesterol levels in heterozygous familial hypercholesterolemic patients withdrawing from regular apheresis
- 1 August 2017
- Published by Elsevier in Atherosclerosis
- Vol. 263, e37-e38
Common functional variant LIPA T16P affects HDL composition among patients with heterozygous familial hypercholesterolemia
- 1 August 2017
- Published by Elsevier in Atherosclerosis
- Vol. 263, e37-e38
Common functional variant LIPA T16P affects HDL composition among patients with heterozygous familial hypercholesterolemia
- Open Access
- 1 January 2017
- Published by Japan Atherosclerosis Society in Journal of Atherosclerosis and Thrombosis
- Vol. 24 (3) , 189-207
Half a Century Tales of Familial Hypercholesterolemia (FH) in Japan
Familial hypercholesterolemia (FH) is a disease characterized by a triad: elevated low-density lipoprotein (LDL) cholesterol, tendon xanthomas, and premature coronary heart disease. Thus, it can be considered as a model disease for hypercholesterolemia and atherosclerotic cardiovascular disease (ASCVD). For the diagnosis of hetero-FH, the detection of Achilles tendon xanthomas by palpation or on X-ray is an indispensable diagnostic skill in clinical lipidology. To prevent the under-diagnosis and under-treatment of FH, the diagnostic criteria should be more convenient and user-friendly. For a patient with cutaneous or tendon xanthomas, the probability of FH is very high; however, an absence of xanthoma does not rule out FH.Brown and Goldstein elucidated the pathogenesis of FH by their work on LDL-receptor (LDL-R), for which they were awarded the Nobel Prize in 1985. In the 1950s, FH patients were divided into heterozygous (hetero-) and homozygous (homo-) FH, and diagnosing homo- and hetero-FH based on the phenotypic features of ASCVD or xanthomas frequently became difficult without the DNA analysis of FH genes. It is estimated that heterozygous mutations in the LDL-R or the proprotein convertase subtilisin/kexin type 9 (PCSK9) gene will be found at a combined frequency of 0.005, which corresponds to 1/199 people in the general population in Japan.Statins and anti-PCSK9 monoclonal antibodies are highly specific and efficient drugs for treating hetero- or homo-FH patients. Most clinical studies have reported an amelioration of ASCVD using long-term statin therapy. Clinical results using anti-PCSK9 monoclonal antibodies will emerge in a few years. In homo-FH patients, mipomersen and lomitapide are expected to yield good results. It is important to sequentially unravel the unrecognized pathogenetic mechanisms of FH to reduce its under-recognition and develop new management strategies for it.
- 1 January 2017
- Published by Japan Atherosclerosis Society in Journal of Atherosclerosis and Thrombosis
- Vol. 24 (3) , 189-207
Open AccessHalf a Century Tales of Familial Hypercholesterolemia (FH) in Japan
Familial hypercholesterolemia (FH) is a disease characterized by a triad: elevated low-density lipoprotein (LDL) cholesterol, tendon xanthomas, and premature coronary heart disease. Thus, it can be considered as a model disease for hypercholesterolemia and atherosclerotic cardiovascular disease (ASCVD). For the diagnosis of hetero-FH, the detection of Achilles tendon xanthomas by palpation or on X-ray is an indispensable diagnostic skill in clinical lipidology. To prevent the under-diagnosis and under-treatment of FH, the diagnostic criteria should be more convenient and user-friendly. For a patient with cutaneous or tendon xanthomas, the probability of FH is very high; however, an absence of xanthoma does not rule out FH.Brown and Goldstein elucidated the pathogenesis of FH by their work on LDL-receptor (LDL-R), for which they were awarded the Nobel Prize in 1985. In the 1950s, FH patients were divided into heterozygous (hetero-) and homozygous (homo-) FH, and diagnosing homo- and hetero-FH based on the phenotypic features of ASCVD or xanthomas frequently became difficult without the DNA analysis of FH genes. It is estimated that heterozygous mutations in the LDL-R or the proprotein convertase subtilisin/kexin type 9 (PCSK9) gene will be found at a combined frequency of 0.005, which corresponds to 1/199 people in the general population in Japan.Statins and anti-PCSK9 monoclonal antibodies are highly specific and efficient drugs for treating hetero- or homo-FH patients. Most clinical studies have reported an amelioration of ASCVD using long-term statin therapy. Clinical results using anti-PCSK9 monoclonal antibodies will emerge in a few years. In homo-FH patients, mipomersen and lomitapide are expected to yield good results. It is important to sequentially unravel the unrecognized pathogenetic mechanisms of FH to reduce its under-recognition and develop new management strategies for it.
- Open Access
- 1 November 2014
- Published by Elsevier in Molecules and Cells
- Vol. 37 (11) , 777-784
Cholesteryl Ester Transfer Protein (CETP) Deficiency and CETP Inhibitors
Hiroshi Mabuchi, Atsushi Nohara, and Akihiro Inazu. Mol. Cells 2014;37:777-84. https://doi.org/10.14348/molcells.2014.0265
- 1 November 2014
- Published by Elsevier in Molecules and Cells
- Vol. 37 (11) , 777-784
Open AccessCholesteryl Ester Transfer Protein (CETP) Deficiency and CETP Inhibitors
Hiroshi Mabuchi, Atsushi Nohara, and Akihiro Inazu. Mol. Cells 2014;37:777-84. https://doi.org/10.14348/molcells.2014.0265
- 1 September 2014
- Published by Elsevier in Atherosclerosis
- Vol. 236 (1) , 54-61
Genotypic and phenotypic features in homozygous familial hypercholesterolemia caused by proprotein convertase subtilisin/kexin type 9 (PCSK9) gain-of-function mutation
- 1 September 2014
- Published by Elsevier in Atherosclerosis
- Vol. 236 (1) , 54-61
Genotypic and phenotypic features in homozygous familial hypercholesterolemia caused by proprotein convertase subtilisin/kexin type 9 (PCSK9) gain-of-function mutation
- 1 August 2013
- Published by Taylor & Francis in Clinical Lipidology
- Vol. 8 (4) , 387-389
MTP inhibitor for treating severe LDL cholesterolemia
- 1 August 2013
- Published by Taylor & Francis in Clinical Lipidology
- Vol. 8 (4) , 387-389
MTP inhibitor for treating severe LDL cholesterolemia
- 1 January 2013
- Vol. 51 (1) , 12-8
Effects of coenzyme Q(10) on LDL oxidation in vitro.
Coenzyme Q(10), a lipid soluble benzoquinone, has excellent antioxidant and membrane stabilizing properties in the cardiac tissue. The present study quantitatively investigated the effects of coenzyme Q(10) on in vitro LDL oxidation. The formation of conjugated dienes, malondialdehyde (MDA) and electrophoretic mobility were monitored as markers of the oxidation of LDL, respectively. Coenzyme Q(10) showed a decrease the formation of conjugated dienes and MDA, respectively, against oxidation in vitro. Coenzyme Q(10) also reduced electrophoretic mobility of the oxidized human LDL. Thus, results showed that the coenzyme Q(10) exhibits strong antioxidant activity in CuSO(4)-mediated oxidation of LDL (P<0.05) in vitro. The inhibitory effects of the coenzyme Q(10) on LDL oxidation were dose-dependent at concentrations ranging from 20 nM to 300 nM. Moreover, the effects of coenzyme Q(10) on LDL oxidation were compared with vitamin E and vitamin C. This study showed that coenzyme Q(10) is a potent antioxidant to protect LDL against oxidation in vitro and may be a good alternative to reduce the risk of atherosclerosis and coronary heart disease and other free radical associated health problems.
- 1 January 2013
- Vol. 51 (1) , 12-8
Effects of coenzyme Q(10) on LDL oxidation in vitro.
Coenzyme Q(10), a lipid soluble benzoquinone, has excellent antioxidant and membrane stabilizing properties in the cardiac tissue. The present study quantitatively investigated the effects of coenzyme Q(10) on in vitro LDL oxidation. The formation of conjugated dienes, malondialdehyde (MDA) and electrophoretic mobility were monitored as markers of the oxidation of LDL, respectively. Coenzyme Q(10) showed a decrease the formation of conjugated dienes and MDA, respectively, against oxidation in vitro. Coenzyme Q(10) also reduced electrophoretic mobility of the oxidized human LDL. Thus, results showed that the coenzyme Q(10) exhibits strong antioxidant activity in CuSO(4)-mediated oxidation of LDL (P<0.05) in vitro. The inhibitory effects of the coenzyme Q(10) on LDL oxidation were dose-dependent at concentrations ranging from 20 nM to 300 nM. Moreover, the effects of coenzyme Q(10) on LDL oxidation were compared with vitamin E and vitamin C. This study showed that coenzyme Q(10) is a potent antioxidant to protect LDL against oxidation in vitro and may be a good alternative to reduce the risk of atherosclerosis and coronary heart disease and other free radical associated health problems.
- Open Access
- 1 February 2011
- Published by Elsevier in Atherosclerosis
- Vol. 214 (2) , 404-407
Molecular genetic epidemiology of homozygous familial hypercholesterolemia in the Hokuriku district of Japan
- 1 February 2011
- Published by Elsevier in Atherosclerosis
- Vol. 214 (2) , 404-407
Open AccessMolecular genetic epidemiology of homozygous familial hypercholesterolemia in the Hokuriku district of Japan
- Open Access
- 29 October 2010
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 4 (1) , 347
A possible new syndrome with double endocrine tumors in association with an unprecedented type of familial heart-hand syndrome: a case report
Introduction: The combination of a pituitary prolactinoma and an aldosterone-producing adrenal adenoma is extremely rare. To the best of our knowledge, double endocrine tumors in association with heart-hand syndrome have not previously been reported. Case presentation: A 21-year-old Japanese woman presented with galactorrhea and decreased visual acuity. A large pituitary adenoma with an increased level of serum prolactin was apparent by computed tomography. She additionally showed mild hypertension (136/90 mmHg) accompanied by hypokalemia. The plasma aldosterone concentration was increased. Computed tomography showed a mass in the right adrenal gland. No other tumors were found despite extensive imaging studies. Physical and radiographic examinations showed skeletal malformations of the hands and feet, including hypoplasia of the first digit in all four limbs. An atrial septal defect was demonstrated by echocardiography. Similar digital and cardiac abnormalities were detected in our patient's father, and a clinical diagnosis of hereditary heart-hand syndrome was made. Conclusion: No established heart-hand syndrome was wholly compatible with the family's phenotype. Her father had no obvious endocrine tumors, implying that the parent of transmission determined variable phenotypic expression of the disease: heart-hand syndrome with multiple endocrine tumors from the paternal transmission or no endocrine tumor from the maternal transmission. This suggests that the gene or genes responsible for the disease may be under tissue-specific imprinting control.
- 29 October 2010
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 4 (1) , 347
Open AccessA possible new syndrome with double endocrine tumors in association with an unprecedented type of familial heart-hand syndrome: a case report
Introduction: The combination of a pituitary prolactinoma and an aldosterone-producing adrenal adenoma is extremely rare. To the best of our knowledge, double endocrine tumors in association with heart-hand syndrome have not previously been reported. Case presentation: A 21-year-old Japanese woman presented with galactorrhea and decreased visual acuity. A large pituitary adenoma with an increased level of serum prolactin was apparent by computed tomography. She additionally showed mild hypertension (136/90 mmHg) accompanied by hypokalemia. The plasma aldosterone concentration was increased. Computed tomography showed a mass in the right adrenal gland. No other tumors were found despite extensive imaging studies. Physical and radiographic examinations showed skeletal malformations of the hands and feet, including hypoplasia of the first digit in all four limbs. An atrial septal defect was demonstrated by echocardiography. Similar digital and cardiac abnormalities were detected in our patient's father, and a clinical diagnosis of hereditary heart-hand syndrome was made. Conclusion: No established heart-hand syndrome was wholly compatible with the family's phenotype. Her father had no obvious endocrine tumors, implying that the parent of transmission determined variable phenotypic expression of the disease: heart-hand syndrome with multiple endocrine tumors from the paternal transmission or no endocrine tumor from the maternal transmission. This suggests that the gene or genes responsible for the disease may be under tissue-specific imprinting control.
- 1 December 2007
- Published by Elsevier in Atherosclerosis
- Vol. 195 (2) , e182-e189
Effects of CoQ10 supplementation on plasma lipoprotein lipid, CoQ10 and liver and muscle enzyme levels in hypercholesterolemic patients treated with atorvastatin: A randomized double-blind study
- 1 December 2007
- Published by Elsevier in Atherosclerosis
- Vol. 195 (2) , e182-e189
Effects of CoQ10 supplementation on plasma lipoprotein lipid, CoQ10 and liver and muscle enzyme levels in hypercholesterolemic patients treated with atorvastatin: A randomized double-blind study